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Introduction
Endocrine disrupting chemicals (EDCs) are natural and 
man-made chemicals acting via mimicking or blocking 
natural hormone functions in the body1. EDCs can 
exhibit significant influence towards various hormonal 
systems, such as estrogen, androgen, progestagen, 
corticosteroid and thyroid signaling systems1. Bisphenol 
A (BPA) has been widely used as monomer for the 
production of  polycarbonate and a precursor of  epoxy 
resins2. Human can be frequently exposed to BPA via 
multiple sources, and babies are considered to be the 
most sensitive group to exposure of  BPA3. For example, 
babies that are not breast-fed,
might drink powdered or liquid milk formula, and 
the cans of  milk formula might release BPA into milk 
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of  BPA has been closely correlated with a variety of  
diseases, including cardiovascular disease and diabetes4,5. 
Additionally, the increased exposure of  BPA is closely 
correlated with increased inflammation and oxidative 
stress 6.  
Drug-metabolizingenzymes-catalyzed biotransforma-
tion process is one of  the most important elimination 
pathways. BPA has been demonstrated to mainly un-
dergo UDP-glucuronosyltransferases (UGTs) catalyzed 
glucuronidation reaction, and UGT2B15 was demon-
strated to be the major UGT isoform 7,8, indicating the 
good interaction between BPA and UGT2B isoforms. 
Given that UGT2B isoforms are involved in the meta-
bolic elimination of  many clinical drugs, the potential 
influence of  BPA administration towards the drug me-
tabolism was speculated. Zidovudine (AZT), the first 
U.S. government approved drug for antiretroviral treat-
ment (ART), has been clinically used and prescribed 
under the name Retrovir. AZT has a narrow therapeu-
tic index, and is mainly metabolized through UGT2B 
isoforms-catalyzed biotransformation reaction 9. In the 
present study, the inhibition capability of  BPA towards 
the typical substrate of  UGT2B zidovudine (AZT) was 
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Abstract
Background: Humans can be frequently exposed to Bisphenol A (BPA) via multiple sources, and babies are considered to 
be the most sensitive group to exposure of  BPA. 
Aims: To investigate the inhibition potential of  BPA towards human liver microsomes (HLMs)-catalyzed zidovudine (AZT) 
glucuronidation.
Materials and Methods: In vitro HLMs incubation system was used to investigate the inhibition potential of  BPA towards 
AZT glucuronidation. Both Dixon and Lineweaver-Burk plots were employed to determine the inhibition kinetic type, and 
nonlinear repression was utilized to calculate the inhibition kinetic parameters (Ki).
Results: Concentration-dependent inhibition of  BPA towards AZT glucuronidation was observed. Both Dixon and 
Lineweaver-Burk plots showed that BPA exerted competitive inhibition towards the glucuronidation of  AZT, and nonlinear 
repression with competitive equation was used to calculate the Ki value to be 3.2 μM.
Conclusion: Potential BPA-AZT interaction might occur when the patients administered with AZT is also exposed to 
BPA.
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evaluated, trying to indicate the possible influence en-




Bisphenol A (purity≥99%), 3’-azido-3’-deoxythimidine 
(AZT), Tris-HCl, alamethicin and uridine 5’-diphos-
phoglucuronic acid (UDPGA) (trisodium salt) were 
obtained from Sigma-Aldrich (St Louis, MO). Mixed 
pooled human liver microsomes (HLMs) from 25 do-
nors were purchased from Research Institute for Liver 
Diseases (RILD, Shang Hai, China). 
AZT glucuronidation assays and analysis method
500 μM of  AZT was used to incubate in the human 
liver microsomal incubation system (0.5 mg/ml of  
HLM, 5 mM UDPGA, 5 mM MgCl2, 50 mM Tris-HCl 
buffer (pH 7.4), 50 μg/mg protein alamethicin). The 
incubation time was 20 min, and the analysis of  AZT 
glucuronidation was performed on HPLC system. The 
HPLC column was eluted at 1 ml/min with a mobile 
phase of  acetonitrile:aqueous containing 0.2% formic 
acid (v:v=12:88). The detection wavelength was set at 
267 nm. The standard curve of  AZT was employed 
to quantify the AZT metabolite due to the lack of  the 
standard of  AZT glucuronide.
Determination of  BPA’s inhibition towards the glucuronidation 
reaction of  AZT
Inhibition ability of  different concentrations of  BPA 
towards the glucuronidation of  AZT was determined, 
and the IC50 value was determined as previously 
described 10. The reaction velocity was determined 
at multiple concentrations of  BPA and AZT. Dixon 
plot (1/reaction velocity versus the concentration of  
BPA) and Lineweaver-Burk plot (1/reaction velocity 
versus 1/[the concentration of  AZT]) were employed 
to determine the inhibition kinetic type, and nonlinear 
regression equation was performed using the equations 




Where the items are defined as followed: V is the 
reaction velocity, [S] and [I] are the concentrations of  
substrate and inhibitor, respectively. Km value is the 
substrate concentration in which the velocity reached to 
half  of  the maximum velocity (Vmax) of  the reaction. 
Ki value is the inhibition constant.  
Results
The concentration-dependent inhibition behaviour 
of  BPA towards human liver microsomes (HLMs)-
catalyzed AZT glucuronidation was firstly investigated 
using multiple concentrations of  BPA. The results (Fig. 
1) showed that the activity of  AZT glucuronidation 
was inhibited by -7.6%, -10.9%, -16.4%, -7.9%, -5.1%, 
-2.1%, 19.1%, 33.7%, and 50% by 0.1, 0.5, 1, 5, 10, 20, 
40, 80, and 100 μM of  BPA. 
Fig. 1 Concentration-dependent inhibition of  BPA towards human liver microsomes (HLMs)-catalyzed zidovudine 
(AZT) glucuronidation. The used concentration of  BPA was 0.1, 0.5, 1, 5, 10, 20, 40, 80, and 100 μM.  
Dixon plot (Fig. 2A) and Lineweaver-Burk plot (Fig. 2B) 
have been regarded to be the most common methods 
to determine the inhibition type. 
Fig. 2 Determination of  inhibition kinetic type for 
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BPA’s inhibition towards HLMs-catalyzed zidovudine 
(AZT) glucuronidation. (A) Dixon plot for BPA’s 
inhibition towards HLMs-catalyzed zidovudine (AZT) 
glucuronidation. (B) Lineweaver-Burk plot for BPA’s 
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inhibition towards HLMs-catalyzed zidovudine (AZT) 
glucuronidation. Each data point represents the  mean
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of  duplicate experiment. Fig. 3 and parameter (Ki) 
The intersection point was located in the second 
quadrant and verticle axis in the Dixon and Lineweaver-
Burk plot, respectively. The inhibition kinetic parameter 
(Ki) was calculated to be 3.2 μM through the data fitting 
with competitive inhibition equation (Fig. 3).
Discussion
Humans will be exposed to numerous xenobiotics 
everyday, such as food, drugs, herbs, and environmental 
pollutants. Therefore, the interaction among the 
compounds existed in these substances will occur, 
including drug-drug interaction and herb-drug 
interaction. All these interactions are mainly induced 
through affecting the pharmacokinetic behaviour, 
especially for the influence towards the metabolism 
of  compounds. Many great efforts have been given 
to cytochrome P450 (CYP) which has been the most 
important DME involved in the metabolism of  most 
of  clinical drugs, and many compounds have been 
demonstrated to inhibit the activity of  CYP isoforms. 
For example, the potential anti-tumor drug noscapine 
can inhibit the activity of  CYP3A4 and CYP2C9 to 
explain the clinical noscapine-warfarin interaction11. The 
herbal components ginsenosides have been reported to 
exhibit inhibition towards the activity of  several CYP 
isoforms 12. Halogenated aromatic compounds (HACs) 
have been reported to inhibit CYP 1A2-dependent 
MROD activity 13.
The important role of  UDP-glucuronosyltransferases 
(UGTs) in the metabolic elimination of  xenobiotics and 
endogenous substances has been drawing more and 
more attention in recent years 14, and some compounds 
have been observed to show inhibitory potential towards 
UGT isoforms. For example, ketoconazole has high 
potential to inhibit lorazepam clearance to a clinically 
significant extent through affecting the glucuronidation 
of  R- and S-Lorazepam 15. The inhibition of  ginsenosides 
towards several UGT isoforms have been suspected to 
be a potential reason for ginseng-drugs interaction 16.  
In the present study, we tried to investigate the 
inhibition of  HLMs-catalyzed AZT glucuronidation 
by BPA which is an important endocrine disrupting 
chemical. Possible BPA-AZT interaction was indicated 
due to the competitive inhibition of  BPA towards the 
glucuronidation of  AZT with relatively low Ki value. 
Additionally, some previous literatures have indicated 
that the addition of  bovine serum albumin (BSA) in 
the incubation system mgiht significantly influence the 
in vitro inhibition parameters17. Therefore, different 
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inhibition kinetic parameters might be obtained if  the 
BSA was added in the in vitro incubation system. It 
should be noted that BPA can inhibit the activity of  
another important UGT isoform UGT1A6 when using 
serotonin (5-HT) and 4-methylumbelliferone (4-MU) as 
the probe substrates 18. All these results indicated that 
exposure of  BPA will affect the metabolic elimination 
of  some clinical drugs through influencing the activity 
of  UGT isofomrs. 
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